JPRN-jRCT1030230280
Recruiting
未知
Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational study - Tezepelumab PRO study
Tashiro Naoki0 sites90 target enrollmentStarted: August 5, 2023Last updated:
Conditionsasthma
Overview
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Tashiro Naoki
- Enrollment
- 90
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- >= 18age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •1\. Patients aged \>\=18 years who provide informed consent and who receive new prescription of Tezepelumab as per the physician's decision at baseline according to the package insert saying Tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)
- •2\. ACQ\-6 \>\=1\.5 at baseline
- •3\. Patients with persistent cough \>\=8 weeks up until the baseline visit according to The Japanese Respiratory Society Guidelines for the Management of Cough and Sputum 2019
Exclusion Criteria
- •1\. Patients who had asthma exacerbation within one month before study enrollment
- •2\. Patients who had the biologics treatment in following period prior to the enrollment
- •\-omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount
- •\-mepolizumab in 4 weeks
- •\-Benralizumab in 8 weeks
- •\-Dupilumab in 2 weeks
- •3\. Patients with cough related diseases other than asthma as determined by treating physicians
- •4\. Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases)
- •5\. Any disorder, including heart failure, malignancy, morbid obesity(BMI\>\=35\) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could:
- •\- Affect the safety of the patient throughout the study
Investigators
Similar Trials
Completed
Not Applicable
Tezepelumab PRO StudyAsthmaNCT05922891AstraZeneca92
Completed
Phase 3
Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe AsthmaAsthmaNCT05280418McMaster University27
Completed
Not Applicable
Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-AnalysisBronchial asthmaJPRN-UMIN000044672Showa University School of Medicine5,524
Not yet recruiting
Not Applicable
Tezepelumab Treatment in Korean Severe Asthma PatientsAsthmaNCT06438913Asan Medical Center100
Not yet recruiting
Phase 1
A clinical study on improvement of asthma control level in patients with refractory asthma by Ba-Duan-Jin lung rehabilitation exerciseITMCTR2000003858Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine